First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 80
- Registration Number
- NCT05141149
- Locations
- 🇺🇸
Northwell Health / R.J. Zuckerberg Cancer Center, New Hyde Park, New York, United States
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
🇪🇸Hospital Universitario La Paz, Madrid, Spain
To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 324
- Registration Number
- NCT05108259
- Locations
- 🇪🇸
Unidad de Fase I. U. Autonoma de Madrid (Clinical Trials Unit, UAM) C/ Arzobispo Morcillo 4, Madrid, Spain
A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 105
- Registration Number
- NCT03776240
- Locations
- 🇦🇺
Q Pharm, Brisbane, Australia
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 119
- Registration Number
- NCT03390673
- Locations
- 🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 650
- Registration Number
- NCT03390686
- Locations
- 🇭🇺
Tudogyogyintezet Torokbalint, Törökbálint, Hungary
🇧🇾Alexandrov Cancer Center, Minsk, Belarus
🇭🇷CHC Osijek, Osijek, Osijecko-baranjska, Croatia
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 503
- Registration Number
- NCT03013504
- Locations
- 🇧🇾
Minsk Clinical Oncological Dispensary, Minsk, Belarus
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇮🇹Modena Hospital, Modena, Italy
© Copyright 2024. All Rights Reserved by MedPath